Menu
Search
|

Menu

Close
X

Cascadian Therapeutics Inc CASC.OQ (NASDAQ Stock Exchange Global Select Market)

10.00 USD
-- (--)
As of Feb 22
chart
Previous Close 10.00
Open --
Volume --
3m Avg Volume 139,445
Today’s High --
Today’s Low --
52 Week High 10.20
52 Week Low 3.20
Shares Outstanding (mil) 50.56
Market Capitalization (mil) 505.60
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.876
FY16
-3.367
FY15
-2.018
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
4.06
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-48.47
13.67
Return on Equity (TTM)
vs sector
-49.46
15.40

EXECUTIVE LEADERSHIP

Christopher Henney
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Scott Myers
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Julia Eastland
Chief Financial Officer, Vice President - Corporate Development, Secretary, Since 2010
Salary: $300,000.00
Bonus: $68,250.00
Gary Christianson
Chief Operating Officer, Since 2007
Salary: $319,300.00
Bonus: $68,171.00
Scott Peterson
Chief Scientific Officer, Since 2012
Salary: $315,000.00
Bonus: $75,521.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3101 Western Ave Ste 600
SEATTLE   WA   98121-3047

Phone: +1206.8012100

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

SPONSORED STORIES